Prohibitin (PHB) is indispensable for Ras-induced Raf-1 activation, cell migration and growth; however, the exact role of PHB in the molecular pathogenesis of cancer metastasis remains largely unexamined. Here, we found a positive correlation between plasma membrane-associated PHB and the clinical stages of cancer. The level of PHB phosphorylated at threonine 258 (T258) and tyrosine 259 (Y259) in human cancer-cell membranes correlated with the invasiveness of cancer cells. Overexpression of phosphorylated PHB (phospho-PHB) in the lipid-raft domain of the cell membrane enhanced cell migration/invasion through PI3K/Akt and Raf-1/ERK activation. It also enhanced epithelial --mesenchymal transition, matrix metalloproteinase-2 activity and invasiveness of cancer cells in vitro. Immunoprecipitation analysis demonstrated that phospho-PHB associated with Raf-1, Akt and Ras in the membrane and was essential for the activation of Raf-1 signaling by Ras. Mice implanted with cancer cells stably overexpressing PHB in the plasma membrane showed enlarged cervical tumors, enhanced metastasis and shorter survival time compared with mice implanted with cancer cells without PHB overexpression. Dephosphorylation of PHB at T258 by site-directed mutagenesis diminished the in vitro and in vivo effects of PHB. These results suggest that increase in phospho-PHB T258 in the raft domain of the plasma membrane has a role in the Ras-driven activation of PI3K/Akt and Raf-1/ERKsignaling cascades and results in the promotion of cancer metastasis.
INTRODUCTION
Ras is an important proto-oncogene residing in the genome of normal cells. Activated Ras may regulate cellular proliferation, migration, invasion via several important downstream effectorsignaling pathways, notably Raf-1/MAPK(ERK), PI3K/Akt and RalGEF/Ral cascade. 1 --3 Among these downstream pathways, Raf-1 was the first bona fide mammalian Ras effector identified. 4, 5 Although Ras may bind directly to Raf-1, it has been shown that full activation of Raf-1 requires prohibitin (PHB, also known as PHB1). 6, 7 PHB is a highly conserved and ubiquitously expressed protein with pleiotropic functions in cell senescence, cell-cycle control, apoptosis and stabilization of mitochondrial proteins. 8, 9 PHB directly interacts with Raf-1 and is required for the displacement of 14-3-3 from Raf-1 by active Ras to facilitate membrane localization, phosphorylation at S338 and full activation of Raf-1 that regulates epithelial cell adhesion and migration. 10 Although PHB mainly localizes to the mitochondria, it is also found in the cytosol, nucleus, lipid rafts, and cell plasma membrane. 7, 11, 12 Whether localization of PHB has any role in the activation of Raf-1 by Ras is unknown. PHB contains multiple phosphorylation sites and it has been reported that insulin phosphorylates PHB at Y114 and Y259, 13 whereas Akt phosphorylates PHB at T258.
14 But, whether phosphorylated PHB (phospho-PHB) has a critical role in the activation or inactivation of Raf-1 is unclear. Expression of cellular PHB is increased in a variety of cancers. 15 --18 So far, however, no consensus on the functions of PHB in cancer cells has been reached. PHB is required for cancer-cell proliferation, whereas overexpression of PHB inhibits growth of breast cancer and androgen-dependent prostate cancer cells. 19 --21 A recent study has shown that the increased expression of surface-PHB in A549 lung cancer cells prevents the apoptosis of cancer cells and renders them more resistant to paclitaxel. 12 PHB has also been shown to be required for cancer-cell adhesion. 21 However, whether plasma membrane-associated PHB or phospho-PHB is associated with metastatic progression of cancer cells has yet to be investigated.
In this study, we show that the level of phospho-PHB in the plasma membrane correlates with the invasiveness of human cancer cells. Stable expression of phospho-PHB in the plasma membrane of HeLa and CL1-0 human cancer-cell lines enhanced epithelial--mesenchymal transition (EMT), as well as invasiveness, and promoted in vivo cancer metastasis in a xenograft murine model. Further, by using PHB phosphorylation site mutants, we demonstrated that the phosphorylation of PHB at T258 has a critical role in the association of PHB with Raf-1, as well as the enhancement of Raf-1 activation and the invasive capability of cancer cells.
RESULTS

Levels of plasma membrane-associated PHB correlate with cancer-cell metastasis
To examine the relationship between plasma membrane-associated PHB expression and cancer-cell metastasis, we analyzed the distribution of plasma membrane-associated PHB in human cervical cancer tissues at different clinical stages and pathological grades in cervix cancer tissue arrays. For this analysis, we used the rhodamine-tagged peptide CKGGRAKDC, which is known to bind PHB in adipose endothelial cells and drug-resistant lung cancer cells, 12, 22 to measure both the intensity and percentage of expression of PHB in the circumferential cell plasma membrane in the tissue array cells (Supplementary Figure 1) . Our results showed higher levels of plasma membrane-associated PHB in the tumor cells versus the normal cells (Figure 1a) , in cancer cells that metastasized to distant organs (M1) versus non-metastatic cells (M0) (Figure 1b) , and in incidences with regional lymph node metastasis (N1) versus those without regional lymph node involvement (N0) (Figure 1c) . Similar results were found by staining the cells with anti-PHB antibody (Supplementary Figure 1) . Examination of the level of plasma membrane-associated PHB and the invasiveness of various cancer-cell lines showed that the levels of plasma membrane-associated PHB in invasive cancer cells were generally higher than those in normal cells or in less invasive cancer cells (Figure 2 and Supplementary Figure 2) . The comparative levels of plasma membrane-associated PHB in four cervical cancer-cell lines were: CaSki4SiHa4HeLaXC-33A. This order correlates well with the invasiveness of these cell lines. Similarly, the level of plasma membrane-associated PHB in the highly invasive H1299 and CL1-5 lung cancer-cell lines was greater than that in the minimally invasive CL1-0 cells. Overall, cancer cell lines with enhanced levels of plasma membrane-associated PHB showed increased invasiveness with a Pearson correlation coefficient of r ¼ 0.79, Po0.0001 (Figure 2b ). This result was further confirmed by western blot analysis (Figure 2c ).
Phospho-PHB in the cell membrane correlates with invasiveness of cancer cells Akt has been shown to phosphorylate PHB at threonine 258 (T258), whereas insulin phosphorylates PHB at tyrosine 114 (Y114) and 259 (Y259). 13, 14 As two of these phosphorylation sites are within the Raf-1 binding region of PHB (residues 243 --272) 23 and the Raf-1/ERK-signaling pathway is involved in cell migration and invasion, 10 we examined whether phosphorylation of PHB at T258 and Y259 residue has any role in the invasive capability of the cells. We found that in the plasma membrane PHB was phosphorylated at residues T258 and Y259, whereas in the cytosol fraction, little, if any, PHB was phosphorylated at these two positions (Figure 2c ). In addition, the levels of phosphorylation of PHB at T258 and Y259 were greater in CL1-5 and CaSki than in CL1-0 and HeLa cells (Figure 2c ). We further analyzed the levels of phospho-PHB in various cancer cell lines by western blot analysis. The levels of PHB phosphorylated at T258 and Y259 in invasive cancer cells were generally higher than those in normal cells or in less invasive cancer cells (Figure 2d ). These results suggest that the level of phospho-PHB in the cell membrane correlates with invasive ability of cancer cells.
Overexpression of phospho-PHB in raft domain of plasma membrane enhances cell migration/invasion through Raf-1/ERK activation Knockdown of PHB in HeLa cells has led to the suggestion that PHB has a critical role in epithelial cell migration and adhesion of cells to the extracellular matrix. 10, 21 To explore the potential role of phospho-PHB in tumor-cell invasion, we constructed a pD-PHB plasmid that expressed PHB fused with the platelet-derived growth factor receptor (PDGFR) transmembrane domain at the C-terminus to anchor the expressed protein to the membrane and tagged with hemagglutinin (HA) epitope at the N-terminus. As a comparison, we also constructed a pBio-PHB plasmid that expressed PHB tagged with biotin at the N-terminus. HeLa cells transfected with pD-PHB expressed exogenous PHB only in the membrane raft, whereas PHB tagged with biotin (Bio-PHB) was expressed in both the raft and non-raft fraction after pBio-PHB transfection (Figure 3a) . Phosphorylation of exogenous PHB at T258 and Y259 was found in the raft but not the non-raft fraction (Figure 3a) . Interestingly, raft-associated Raf-1 was found in pD-PHB but not in empty vector or pBio-PHB-transfected cells. The migration and invasive abilities of HeLa cells transfected with pD-PHB were increased approximately threefold in comparison with cells transfected with vector or pBio-PHB (Figure 3b ). Similar enhancement in migration and invasiveness was observed in CL1-0 lung cancer cells transfected with pD-PHB (Figure 3b ). Taken together, these results indicate that the levels of lipid raft anchored phospho-PHB correlate positively with cell migration and invasiveness.
As PHB has been reported to be required for Ras-induced Raf-MEK-ERK activation and cell migration, 10 we then examined whether membrane-associated phospho-PHB would activate the Raf-1/ERK pathway without Ras induction. We found that phosphorylation of ERK and Raf-1 S338 but not B-Raf was enhanced significantly in HeLa or CL1-0 cells transfected with pD-PHB as compared with cells transfected with control vector or pBio-PHB (Figure 3c ). Raf-1 kinase assay verified that HeLa or CL1-0 cells transfected with pD-PHB resulted in higher Raf-1 activation than those transfected with pBio-PHB (Supplementary Figure 3) .
As the C-terminal region of PHB (residues 243 --272) interacts with Raf-1, 6, 23 we further checked whether pD-PHB transfection facilitates more association of phospho-PHB with Raf-1 and Ras by immunoprecipitation with anti-Raf-1 antibody. In cells transfected with pD-PHB, Raf-1 associated with phospho-PHB, Ras and Akt, whereas in cells transfected with vector or pBio-PHB, there was little association between Raf-1 and Ras, or phospho-PHB (Figure 3d ). Similar results were observed using anti-HA antibody to immunoprecipitate lipid raft anchored PHB (raft-PHB) or pulldown of Bio-PHB with streptavidin --agarose bead (SA-bead) (Supplementary Figure 4) . Collectively, these results suggest that phospho-PHB in the raft domain of the plasma membrane may have an important role in the activation of Raf-1.
Phosphorylation of PHB is required for the association with Raf-1 and Ras activation of Raf-1 signaling To further verify that phospho-PHB is required for the activation of Raf-1, we generated a double phosphorylation site mutant pBio-PHB construct in which tyrosine residues Y259 and threonine residue T258 were substituted with phenylalanine (F) and isoleucine (I), respectively. HeLa cells were transfected with wildtype or mutant pBio-PHB-I258/F259 plasmid in the presence or absence of activated Ras and analyzed for the phosphorylation of Raf-1 by western blot analysis. Activated Ras increased phosphoAkt S473 as well as the phosphorylation of endogenous PHB and Bio-PHB at T258 and Y259. These increases were accompanied by an increase of Raf-1 active phosphorylation site (Raf-1 S338 ) and decrease of negative phosphorylation site (Raf To further distinguish the involvement of individual PHB phosphorylation sites on the activation of Raf-1 signaling, we generated three single-phosphorylation-site D-PHB mutant constructs pD-PHB T258I , pD-PHB Y259F and pD-PHB Y114F in which threonine 258, tyrosine 259 and tyrosine 114 were substituted with isoleucine and phenylalanine, respectively. As anticipated, pD-PHB T258I and pD-PHB Y259F led to the expression of raft-PHB mutant protein without phosphorylation at T258 and Y259 that was accompanied by the disappearance of Raf-1 in the raft domain ( Figure 4c ). Interestingly, pD-PHB Y259F resulted in raft-PHB dephosphorylated not only at Y259 but also at T258 (Figure 4c ). Raft-PHB and raft-PHBY114F mutant protein co-immunoprecipitated with Raf-1, whereas raft-PHBT258I, raft-PHBY259F and raft-PHBT258I/Y259F did not (Figure 4d ). Raf-1 and ERK1/2 were phosphorylated only in cells expressing raft-PHBY114F and raft-PHB but not raft-PHBT258I, raft-PHBY259F or raft-PHBT258I/Y259F proteins ( Figure 4d ). Taken together, these results indicate that dephosphorylation of raft-PHB at T258 diminishes the association of PHB with Raf-1 and activation of Raf-1/ERK. Figure 5b) . MMP-2 is known to increase the invasiveness of cancer cells. 24, 25 Further analyses revealed that cells expressing T258I or Y259F raft-PHB mutant protein exhibited an increased level of E-cadherin and decreased levels of Snail and ZEB1 compared with those expressing Y114F and wild-type raft-PHB protein (Figure 5a ). Cells expressing T258I or Y259F raft-PHB mutant protein showed decreases in MMP-2 activity and in migration and invasive ability in comparison with those expressing Y114F mutant or wild-type raft-PHB protein (Figures 5b and c) . Moreover, PHB knockdown in the CL1-5 cells using siRNA decreased EMT, phospho-Raf-1 S338 , phospho-ERK, MMP2 and invasiveness of CL1-5. These inhibitory effects could be reversed by wild type raft-PHB protein but not T258I raft-PHB mutant protein (Supplementary Figure 6) . Taken together, these results suggest that dephosphorylation of raft-PHB at T258 decreases EMT, MMP-2, migration and invasive activity of cancer cells.
CKGGRAKDC
Phospho-PHB enhances tumor growth and metastasis in vivo
To further elucidate the functional role of cell plasma membraneassociated PHB in vivo, we generated a cell line (HeLa D-PHB-GFP ) that stably expresses a PHB-GFP fusion protein in the plasma membrane and a corresponding mock-cell line (HeLa D-GFP ) that expresses only GFP (Supplementary Figure 7) . Flow cytometric analysis showed that more plasma membrane-associated PHB was expressed in HeLa D-PHB-GFP than in HeLa D-GFP or HeLa cells Y114F  Y259F  T258I  vector  wt  Y114F  Y259F  T258I   Y114F  Y259F  T258I  vector  wt  Y114F  Y259F  T258I   Y114F  Y259F  T258I   vector  wt  Y114F  Y259F  T258I  vector  wt  Y114F  Y259F  T258I   vector Taken together, these results suggest that an increased level of plasma membrane-associated PHB in cervical cancer cells facilitates their cervical proliferation, extravasation, and metastatic ability, thus resulting in a decrease in the survival time of animals bearing these cancer cells.
To further elucidate the effect of phosphorylation of PHB at T258 and Y259 on cancer metastasis in vivo, we generated three HeLa cell lines, namely HeLa , that stably expressed fusion proteins of GFP with either T258I, Y259F or T258I/Y259F PHB mutant protein, respectively. Measurement of the invasive ability of each cell line showed that cells stably expressing these PHB mutant proteins were not as invasive as cells expressing wild-type PHB protein (Figure 6a) . Moreover, implantation of these cells into orthotopic cervical cancer xenografts in SCID mice showed that none of the cells containing PHB mutant proteins were as effective as those expressing wild-type PHB protein in promoting cervical tumor growth or cancer-cell metastasis to the lung and liver (Figure 6b ). Consistent with these results, mice bearing cells with the mutant proteins survived significantly longer (T 1/2 ranging from 41 to 52 days) than HeLa D-PHB-GFP -bearing mice (T 1/2 ¼ 34 days, Po0.01) (Figure 6c) . Furthermore, analysis of tumor tissue lysates showed that mice implanted with HeLa D-PHB-GFP but not HeLa
cells had enhanced levels of active Raf-1 and active ERK1/2 and a reduced level of E-cadherin. These in vivo data (Figure 6d ) are thus consistent with our in vitro results (Figures 4 and 5) , suggesting that phospho-PHB at T258 residue has a critical role in the invasion and metastasis of cancer cells.
DISCUSSION
Raf protein kinases are Ras effector proteins that mediate diverse biological functions such as differentiation, migration and growth. 2, 26 Using PHB siRNA, Rajalingam et al. 10 showed that PHB is indispensable for the activation of the Ras/Raf-1-signaling pathway and modulation of epithelial adhesion and migration. Although PHB contains multiple residues that could serve as phosphorylation sites, 13 it has not yet been identified whether phosphorylated or unphosphorylated PHB interacts with Raf-1 and whether such phosphorylation affects cell invasiveness. Here we showed for the first time that the phosphorylation of plasma membrane-associated PHB at T258 has an important role not only in the association of PHB with Raf-1, Ras and Akt, the activation of Raf-1/ERK, and the invasive ability of cancer cells in vitro (Figures 3 and 4) , but also in the metastasis of cancer cells in vivo (Figure 6 ). These effects were reduced in cells expressing PHB dephosphorylated at T258 (Figures 4 and 6) . Our results thus suggest that phospho-PHB in the plasma membrane is indispensable for Raf-1 activation and an aberrant increase in phospho-PHB in the cancer cell plasma membrane may facilitate uncontrollable activation of Raf-1/ERK-signaling cascades, which might push cancer cells into more advanced stages of malignant transformation.
It has been reported that insulin phosphorylates PHB at Y259, whereas Akt phosphorylates PHB at T258.
14 Although both phosphorylation sites are within the Raf-1 binding region of PHB (residues 243 --272), 23 the interaction between these two PHB phosphorylation sites has not been clarified. In this study, we found that a single-point mutation of Y259 to phenylalanine in PHB modulated the phosphorylation of PHB at T258. On the contrary, substitution of T258 with isoleucine in PHB did not affect phosphorylation at Y259 (Figure 4c ). These results suggest that the phosphorylation status of Y259 may have a regulatory role in the phosphorylation of T258 but not vice versa. Moreover, even though Y259 of PHB was phosphorylated in cells expressing T258I mutant of PHB, it did not activate Raf-1; it is thus most likely that phosphorylation of T258 rather than Y259 is critical for the binding of PHB with Raf-1 and the induction of Raf-1 activation.
Raf-1 may influence cell migration via the MEK/ERK and/or ROCKII/MYPT1/MLC2 pathways. 27, 28 We found that raft-PHB increased phosphorylation of both MLC2 and MYPT1, whereas, T258I and Y259F raft-PHB mutant proteins did not (Supplementary Figure 9a) . ROCKII inhibitor Y27632 selectively inhibited raft-PHBmediated phosphorylation of MLC2 and MYPT1, whereas MEK/ERK inhibitor U0126 inhibited phosphorylation of ERK, but not MLC2 and MYPT1 (Supplementary Figure 9b) . These results suggest that phospho-PHB may activate Raf-1 to affect cell migration via both the ROCKII and ERK pathways.
Although the growth and invasive ability of cells containing PHB mutant proteins is comparable to control cells expressing D-GFP as shown in Figures 6a and b , it must be noted that mice bearing cells with the mutant proteins died sooner than control HeLa D-GFP -bearing mice (Figure 6c ). These results seem to suggest that other moieties of PHB that are less essential than phosphorylation of PHB T258 may also have a role in the in vivo effects of the cancer cells after certain period of time.
It has been shown previously that overexpression of PHB inhibits growth of MCF-7 breast-cancer cell line. 20 Here, we found that transfection with pBio-PHB decreased the growth of MCF-7 cells, whereas expression of raft-PHB by transfecting with pD-PHB increased the growth of both MCF-7 and HeLa cell lines (Supplementary Figure 10) . It is thus likely that in both breast and cervical cancer cells, PHB localized in the raft may function as a tumor promoter.
Our results showed for the first time that besides Akt and Raf-1, active Ras also increases phosphorylation of PHB (Figure 4a) . As Akt is known to phosphorylate PHB, 14 our finding that expression of Bio-PHB T258I/Y259F mutant protein attenuated phosphorylation of Raf-1 but not Akt by Ras (Figure 4a ) and that DN-Akt decreased phospho-Akt, phospho-Raf-1 S338 and phospho-ERK but not phosphorylation of PI3Kp85 Y458 in HeLa and CL1-0 cells (Figure 4b ) suggest that active Ras activates PI3K and Akt; phosphorylated Akt then activates PHB and Raf-1 in this sequential order. Moreover, phospho-PHB T258 may serve as a bridge for coordinating two Ras downstream effector-signaling pathways, that is, the PI3K/Akt and Raf-1/MAPK(ERK) cascades.
In summary, we have shown that the level of phospho-PHB in the cell plasma membrane has a critical role in the association of PHB with Raf-1 and in the activation of Raf-1/ERK, induction of EMT and increased MMP-2 activity. Aberrant increase of phospho-PHB in the cell membrane may result in the uncontrollable activation of Raf-1/ERK-signaling pathway leading to the enhancement of the invasive and metastatic capabilities of cancer cells. Thus, molecules or compounds targeting plasma membraneassociated PHB and phosphorylation of PHB may decrease cancer cell metastasis and invasiveness.
MATERIALS AND METHODS
Construction of plasmids
Human PHB cDNA was amplified by PCR from the pOTB7-PHB plasmid (Open Biosystems, Huntsville, AL, USA) and subcloned into the pDisplay vector by Gateway cloning technology (Invitrogen, Carlsbad, CA, USA) to generate plasmid pD-PHB, which fused the PHB gene at the C-terminus to the PDGFR transmembrane domain and tagged it with the HA epitope at the N-terminus, or the pcDNA6/BioEase-DEST vector (Invitrogen) to generate plasmid pBio-PHB to express PHB tagged with biotin. Human PHB cDNA was subcloned into the pEGFP-N1 vector (Clontech, Mountain View, CA, USA) to generate plasmid pPHB-GFP, with the GFP tagged to the C-terminus of PHB. The PHB-GFP or GFP gene was subcloned into the pDisplay vector to obtain the pD-PHB-GFP and pD-GFP plasmids. The PHB mutants were produced using the QuikChange Site-directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA) according to the manufacturer's instructions. The following primers were used for generating the PHB mutants: Y114F, forward-5 0 CAGCATCGGAGAGGACTTTGATGAGCGTGTGC 3 0 and reverse-5 0 GCACACGCTCATCAAAGTCCTCTCCGATGCTG 3 0 ; T258I: forward-5 0 CTCTCGGAACATCATCTACCTGCCAGCGG 3 0 and reverse-5 0 CCGC TGGCAGGTAGATGATGTTCCGAGAG 3 0 ; Y259F, forward-5 0 TCTCGGAACATC ACCTTCCTGCCAGCGG 3 0 and reverse-5 0 CCGCTGGCAGGAAGGTGATGTTCC GAGA 3 0 . All constructs were verified by DNA sequencing. Transfections were performed using FuGENE HD transfection reagent (Roche, Nutley, NJ, USA) according to the manufacturer's protocol. The plasmids pUSEamp, pUSEamp-Akt1 (wild type), pUSEamp-myr-Akt1 (dominant activate), pUSEamp-Akt1 K179M (dominant negative) and pUSE-H-Ras (61L) were purchased from Upstate Biotechnology (Lake Placid, NY, USA).
Fluorescence histochemistry for detection of PHB in plasma membrane of human cervical cancer tissues Human cervical cancer tissue microarray (TMA) slides CR806, CR241 and T102 (with no overlapping cases) were purchased from US Biomax (Rockville, MD, USA) and verified by a qualified, experienced pathologist (Dr Wei-Hwa Lee). TMA samples contained normal cervical tissues and squamous cell carcinoma, including pathological grade, clinical stage, and tumor-node-metastasis classification. In brief, all tissue samples were fixed with formalin, embedded in paraffin and cut to 1.5 mm diameter and 5 mm thickness. After deparaffinizing with xylene, rehydrating with alcohol and antigen retrieval, the slides were blocked with 1% BSA for 1h at room temperature and then stained for PHB by incubating with 1 mM rhodaminetagged CKGGRAKDC peptide (Genemed Synthesis, San Antonio, TX, USA) in the dark at room temperature for 2 h. After washing with phosphate-buffered saline (PBS), the slides were further stained with DAPI (0.5 mg/ml) at room temperature for 1 min and then mounted with Vectashield (Vector Laboratories, Burlingame, CA, USA). The slides were viewed under a confocal microscope (Zeiss LSM 510 META, Carl Zeiss, Jena, Germany), and images with or without rhodamine-tagged CKGGRAKDC peptide were acquired and analyzed using AxioVision 4.6 software (Carl Zeiss).
A four-point staining score was devised for evaluating the relative intensity and expression percentage of plasma membrane-associated PHB in the cells of the tissue array. Cells with circumferential cell plasma membrane staining for PHB were considered as positive, while those without membrane staining were regarded as negative cells (Supplementary Figure 1 ). The percentage of positive cells from three fields of each tissue sample was scored as follows: 0 (0 --1%), 1 (1 --10%), 2 (10 --30%), or 3 (430%). The cellular distribution of PHB throughout the cell was obtained using the profile function of Axiovision 4.6 software and plotted as line intensity histograms (Supplementary Figure 1d, right panel) . The ratio of plasma membrane to cytoplasmic fluorescence intensity (I pm /I cyt ) in ten cells of each tissue sample was used to quantitate the extent of membrane localization of PHB. The average ratio of I pm /I cyt in each tissue sample was scored as follows: 0 (p1), 1 (1-1.5), 2 (1.5 --2) or 3 (X2). Two scores for each tissue sample were combined to evaluate the relative intensity and expression percentage of membrane-associated PHB in each tissue sample.
Isolation of plasma membrane proteins
Plasma membrane extracts were prepared using a plasma membrane protein extraction kit (BioVision, Mountain View, CA, USA). Extraction of plasma membrane and cytosolic proteins were performed according to the manufacturer's instructions. Plasma membrane and cytosolic fractions were tested for the presence of plasma membrane marker Na þ /K þ -ATPase, and cytosolic marker GAPDH by western blot. Membrane raft proteins were extracted as described previously. HeLa cells were transfected with pD-GFP (as a control), pD-GFP-PHB or chimeric mutant constructs of PHB, and then cultured in culture medium supplemented with 1 mg/ml G418. After growth under selection for 2 weeks, cells comprising the brightest 5 to 10% of the population were isolated through several rounds of fluorescence-activated cell sorting. Flow cytometric analysis revealed that more than 99% of cells expressed GFP. Western blot analysis confirmed the expression of the respective proteins in the cell lines.
Establishment of an orthotopic human cervical cancer xenograft model in SCID mice
An orthotopic human cervical cancer xenograft model was established in SCID mice. Briefly, a group of fifteen female SCID mice aged 8 --10 weeks were anesthetized by 0.4% isofluorane inhalation. Following exposure of the uterus by an abdominal midline incision, the top and bottom sites of the cervix were stitched using 4-0 bioabsorbable polyglycolic acid sutures. Cervical cancer cells (5 Â 10 6 cells in 10 ml of PBS) were directly injected into the cervical cavity with a 30G Hamilton syringe.
Statistical analysis
All statistical comparisons were made with two-tailed tests. The survival time was assessed using Kaplan --Meier curves and tested for significance by the log-rank test. Statistical evaluation was performed using GraphPad
